I hereby certify that this correspondence is being deposited with the United

States Postal Service as first class mail in an excellent active seed to

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

TOWNSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GREGORY et al.

Application No.: 10/602,258

Filed: June 23, 2003

For: ADENOVIRAL VECTORS HAVING A PROTEIN IX DELETION Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

Attorney Docket No.: 016930-005000U

§1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 08/328,673, filed October 25, 1994, now U.S. Patent 6,210,939 B1 issued April 3, 2001 (Attorney Docket No. 016930-000920US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

GREGORY et al.

Application No.: 10/602,258

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Chuan Gao Reg. No. 54,111

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834 Tel: 415-576-0200

Fax: 415-576-0300

MTD:mtd 60038912 v1



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

	Complete if Known	
Application Number	10/602,258	
Filing Date	June 23, 2003	
First Named Inventor	Gregory, Richard	
Art Unit	Not Yet Assigned	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	016930-005000US	

		Document Number			
Examiner Initials*	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,210,939 B1	04-03-2001	Gregory et al.	

				FOREIGN PA	TENT DOCUME	ENTS	-	
Examiner Initials*	Cite No.1	Fore	eign Patent Doo Number ⁴		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, L Where Relevan Passages or Relev Figures Appea	t vanta
	AB	WO	94/24297	Kind Code (ii Kilowii)	10/1994		· I iguies Appea	'
			NO	N PATENT LIT	ERATURE DOC	TIMENTS		
Examiner Initials *	Cite No.1		e of the autho	r (in CAPITAL LET al, serial, symposit	TERS), title of the	article (when appropriate) late, page(s), volume-issu		T ²
	AC					d RNA Sequences Tr 5 or 293) Virology 9		
	AD	Subcutaneo	usly or Intra		Treatment of A	Alpha Administered dvanced Malignant D		
	AE	Austin, E.A Colorectal C	. and Huber Carcinoma: (, B.E. "A First	Step in the Deve ncing, and Expr	elopment of Gene The ession of Escherichia		!
	AF	Bacchetti, S	. and Graha	m, F. "Inhibitio	on of cell prolife	ration by an adenovir onal Journal of Onco		
	AG				olrectal Carcino	ma Cell Growth by W	Vild-Type	
	АН	Bartek et al. "Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies." Oncogene 6:1699-1703 (1991).						
	Berkner, Kathleen L. and Sharp, Phillip A. "Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant." Nucleic Acids Research 13(3):841-857 (1985). Boshart et al. "A Very Strong Enhancer Is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus." Cell 41:521-530 (1985).							
							ate Early Gene	
	AK				expression of p A) 87:1973-197	53 gene in human hep 77 (1990).	patocellular	
	AL					iver metastases after i (USA) 90:7024-7028		

	 		 	 	_
Examiner	Date	ł			1
Signature	Considered	ļ			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

SEP 2 2 2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSUR STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet

	C mplete if Known	
Application Number	10/602,258	
Filing Date	June 23, 2003	
First Named Inventor	Gregory, Richard	
Art Unit	Not Yet Assigned	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	016930-005000US	

	FOREIGN PA	TENT DOCUMI	ENTS		
Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶
АМ	Smith, R.R. et al., "Studies of the use of cervix," Cancer 9(6):1211-1218 (1956))			
AN	Research & Therapeutics: Antisense &	Gene Therapy	Abstract S216, Apr.	12-18, 1993.	
AO	Zhang, W.W. et al., "High-efficiency g p53 in human lung cancer cells mediate 1(1):5-13 (1994).	ene transfer and ed by recombin	d high-level expressio ant adenovirus," Cand	on of wild-type c. Gene Ther.	
AP	Challberg, M.D. and Kelly, T.J. PNAS	USA, 76:655-0	559 (1979).		
AQ	Science 250:1576-1580 (1990).				
AR	but not growth rate." Oncogene 6:1799)-1805 (1991).			
AS	p53 Gene." Cancer Research 52:222-2	26 (1992).			
АТ	the Absence of Detectable Polypeptide	IX" Virology	39:977-980 (1981).		<u> </u>
AU	of Experimental Brain Tumors" Science	ce 256:1550-15	52 (1992).		
AV	Proc. Natl. Acad. Sci. USA 88:3155-3	159 (1991).			
Demetri et al. "A Phase I Trial of Recombinant Human Tumor Necrosis Factor and Interferon-Gamma: Effects of Combination Cytokine Administration In Vivo." J. Clin.					
AX	Biology 10:5772-5781 (1990).				
AY	(1993).				
AZ	Transfer of the Herpes Simplex Virus 3:608-614 (1991).	Thymidine Kin	ase Gene." The New	Biologist	<u> </u>
ВА	Oncogene 7:1853-1857 (1992).				
ВВ	Freeman et al. "The "Bystander Effect Mass Is Genetically Modified." Cance	": Tumor Regreer Res. 53:5274-	ession When a Fractio 5283 (1993).	on of the Tumor	
	AM AN AO AP AQ AR AS AT AU AV AW AX AY BA	Cite No.¹ Country Code³ Number⁴ Kind Code³ (Miknown) AM Smith, R.R. et al., "Studies of the use of cervix," Cancer 9(6):1211-1218 (1956) AN Wills, K.N. et al., "Adenovirus vectors Research & Therapeutics: Antisense & Zhang, W.W. et al., "High-efficiency g p53 in human lung cancer cells mediat 1(1):5-13 (1994). AP Challberg, M.D. and Kelly, T.J. PNAS AQ Chen et al. "Genetic Mechanisms of Tomes of Science 250:1576-1580 (1990). AR Chen et al. "Expression of wild-type puber but not growth rate." Oncogene 6:1799 Cheng et al. "Suppression of Acute Ly p53 Gene." Cancer Research 52:222-2 AT Colby, W.W. and Shenk, T.J., "Adeno the Absence of Detectable Polypeptide of Experimental Brain Tumors" Science AU Culver et al. "In Vivo Gene Transfer wo fexperimental Brain Tumors" Science Average and Experimental Brain Tumors and Culver et al. "Lymphocytes as a cellular Proc. Natl. Acad. Sci. USA 88:3155-3 Demetri et al. "A Phase I Trial of Reconstruction of Combin Oncol. 7(10):1545-1553. AX Diller et al. "p53 Functions as a Cell Combin Oncol. 7(10):1545-1553. AX Biology 10:5772-5781 (1990). AY El-Deiry et al. "WAF1, a Potential Met (1993). Ezzidine et al. "Selective Killing of Gintransfer of the Herpes Simplex Virus 3:608-614 (1991). Feinstein et al. "Expression of the norm Oncogene 7:1853-1857 (1992). Freeman et al. "The "Bystander Effect	Cite No.¹ Country Code³ Number⁴ Kind Code³ (# Known)	Country Cooles Number Number Number Number Of Viruses in the treatment of Cited Document Am Smith, R.R. et al., "Studies of the use of viruses in the treatment of carcinor cervix," Cancer 9(6):1211-1218 (1956). AN Wills, K.N. et al., "Adenovirus vectors for gene therapy of cancer," Genetic Research & Therapeutics: Antisense & Gene Therapy Abstract S216, Apr. Zhang, W.W. et al., "High-efficiency gene transfer and high-level expression p53 in human lung cancer cells mediated by recombinant adenovirus," Cancil (1):5-13 (1994). AP Challberg, M.D. and Kelly, T.J. PNAS USA, 76:655-659 (1979). AQ Chen et al. "Genetic Mechanisms of Tumor Suppression by the Human p53 Science 250:1576-1580 (1990). AR Chen et al. "Expression of wild-type p53 in human A673 cells suppresses the but not growth rate." Oncogene 6:1799-1805 (1991). AS Chen et al. "Suppression of Acute Lymphoblastic Leukemia by the Human p53 Gene." Cancer Research 52:222-226 (1992). Colby, W.W. and Shenk, T.J., "Adenovirus Type 5 Virions Can be Assembthe Absence of Detectable Polypeptide IX" Virology 39:977-980 (1981). AU Culver et al. "In Vivo Gene Transfer with Retroviral Vector-Producer Cells of Experimental Brain Tumors" Science 256:1550-1552 (1992). AV Culver et al. "In Vivo Gene Transfer with Retroviral Vector-Producer Cells of Experimental Brain Tumors" Science 256:1550-1552 (1992). AV Culver et al. "In Vivo Gene Transfer with Retroviral Vector-Producer Cells of Experimental Brain Tumors" Science 256:1550-1552 (1992). AV Demetri et al. "P53 Functions as a Cell Cycle Control Protein in Osteosarcom Biology 10:5772-5781 (1990). AY El-Deiry et al. "WAF1, a Potential Mediator of p53 Tumor Suppression." C (1993). Ezzidine et al. "Selective Killing of Glioma Cells in Culture and in Vivo by Transfer of the Herpes Simplex Virus Thymidine Kinase Gene." The New 3:608-614 (1991). Fenstein et al. "Expression of the normal p53 gene induces differentiation Oncogene 7:1853-1857 (1992).	Foreign Patent Document Publication Date Name of Patentee or Applicant of Cited Publication Date MM-DD-YYYY Applicant of Cited Passages or Relevant Passages or Relevan

Date Examiner Considered Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² Applicant is to place a check mark here if English language Translation is attached.

SEP 2 27003 W

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

	Complete if Known	
Application Number	10/602,258	
Filing Date	June 23, 2003	
First Named Inventor	Gregory, Richard	
Art Unit	Not Yet Assigned	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	016930-005000US	

		FOREIGN PA	TENT DOCUME	ENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶			
	ВС	Ghosh-Choudhury et al. "Protein IX, a is essential for the packaging of full ler (1987).	Ghosh-Choudhury et al. "Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes." EMBO Journal 6:1733-1739						
	BD	Gooding et al. "Molecular Mechanisms Immune Defenses." Crit. Rev. Immuno	1. 10:53-71 (19	90).					
	BE	Graham, F.L. and van der Eb, A.J. "Al Human Adenovirus 5 DNA." Virology	52:456-467 (1	973)					
	BF	Graham, F.L. and Prevec, L. Vaccines: W. Ellis (ed.), Boston: Butterworth-He	inemann, 363-3	390 (1992).					
	Heuvel et al. "Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells." EMBO Journal 9:2621-2629 (1990).								
	вн	Hock et al. "Mechanisms of rejection in interleukin 2, interleukin 4, interleukin Proc. Natl. Acad. Sci. USA 90:2774-27	7, tumor necro	or cell-targeted gene to sis factor, or interfero	ransfer of n .gamma"				
	ВІ	Hollstein et al. "p53 Mutations in Hum	an Cancers." S	cience 253:49-53 (199	91).				
	ВЈ	Horwitz, Marshall S. "Adenoviridae ar New York: Raven Press, 1679-1721 (1		ation." sVirology B.N	. Fields (ed.),				
 	ВК	Horvath, J. and Weber, J.M. "Nonpern to Adenovirus Type 2 Infection." J. Vi	nissivity of Hur rol. 62:341-345	nan Peripheral Blood (1988).	Lymphocytes				
****	BL	Huang et al. "A cellular protein that co retinoblastoma gene product." Nature 3	mpetes with SV	740 T antigen for bind	ling to the				
	ВМ	Huber et al. "Retroviral-mediated gene carcinoma: An innovative approach for 88:8039-8043 (1991).	therapy for the	treatment of hepatoc	ellular Sci. USA				
	BN	Hunter, T. "Braking the Cycle." Cell 7	5:839-841 (199	3).					
	во	Jones, N. and Shenk, T. "Isolation of A Defective for Transformation of Rat E	mbryo Cells." (Cell 17:683-689 (1979	9).				
	ВР	Kamb et al. "A Cell Cycle Regulator P Types." Science 264:436-440 (1994).							
	BQ	Kuerbitz et al. "Wild-type p53 is a cell irradiation." Proc. Natl. Acad. Sci. US	cycle checkpo A 89:7491-749	int determinant follow 5 (1992).	ving				

Examiner	Date	
Signature	 Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet

(Complete if Known	
Application Number	10/602,258	
Filing Date	June 23, 2003	
First Named Inventor	Gregory, Richard	
Art Unit	Not Yet Assigned	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	016930-005000US	

		FOREIGN PAT	TENT DOCUM	ENTS				
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵		
	BR	Landmann et al. "Prolonged Interferon- Cancer Patients: Differential Response Class I and II Antigens." J. Interferon F	of Serum CD1	4, Neopterin, and Mor	ous Infusion in nocyte HLA			
	BS	Lane, D.P. "p53, guardian of the genon	ne." Nature 358	3:15-16 (1992).				
	вт	Lee et al. "Human Retinoblastoma Susa Sequence." Science 235:1394-1399 (19	987).					
	BU	Lemaistre et al. "Therapeutic effects of in patient with chronic lymphocytic leu	ıkaemia." Lanc	et 337:1124-1125 (19	91).			
	BV	Lemarchand, Patricia. "Adenovirus-me .alphasub.1 -antitrypsin cDNA to hum 89:6482-6486 (1992).	ediated transfer nan endothelial	of a recombinant hun cells." Proc. Natl. Ac	nan ad. Sci. USA			
•	BW	Levine, A.J. "The Tumor Suppressor G	Genes." Annu. F	Rev. Biochem. 62:623	-651 (1993).			
	вх	Lowe et al. "p53 is required for radiation 362:847-852 (1993).						
	BY	Lowe et al. "p53-Dependent Apoptosis Cell 74:957-967 (1993).						
	BZ	Mercer, et al. "Negative growth regular conditionally expresses human wild-ty (1990).	pe p53." Proc.	Natl. Acad. Sci. USA	87:6166-6170	****		
wer.	CA	Metzger, Gerard and Werbin, Harold. Induced Covalent-like Binding of Som Biochemistry 18(4):655-659 (1979).	e Nonhistone I	Proteins to DNA in Ch	romatin."			
<u>.</u>	СВ	Moolten, F.C. "Tumor Chemosensitivity Conferred by Inserted Herpes Thymidine Kinase						
	СС	Nakabayashi et al. "Transcriptional Re	Nakabayashi et al. "Transcriptional Regulation of .alphaFetoprotein Expression by Dexamethasone in Human Hepatoma Cells." The Journal of Biological Chemistry					
	CD	Palmer et al. "Genetically modified ski gradually inactivate introduced genes."	Proc. Natl. Ac	cad. Sci. USA 88:1330	0-1334 (1991).			
	CE	Rao et al. "The adenovirus E1A protein 19-kDa and Bcl-2 proteins." Proc. Nat	1. Acad. Sci. U	SA 89:7742-7746 (19	92).			
	CF	Ravoet et al. "Non-Surgical Treatment Oncology Supplement 3:104-111 (199	of Hepatocarc					
Examine	er		Date					

:xamıner Considered Signature EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

SEP 2 2 2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known				
Application Number	10/602,258			
Filing Date	June 23, 2003			
First Named Inventor	Gregory, Richard			
Art Unit	Not Yet Assigned			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	016930-005000US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Line Where Relevant Passages or Relevar Figures Appear		
	Rich et al. "Development and Analysis of Recombinant Adenoviruses for Gene Therapy of cystic Fibrosis." Human Gene Therapy 4:461-476 (1993).						
	сн	Conductance Regulator Gene to the Airway Epithelium." Cell 68:143-133 (1992). Sarnow et al. "Adenovirus E1b-58kd Tumor Antigen and SV40 Large Tumor Antigen Are					
	CI						
	CJ Shaw et al. "Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line." Proc. Natl. Acad. Sci. USA 89:4495-4499 (1992).					·	
CK Siegfried, W. "Perspectives in Gene Therapy with Recombinant Adenoviruses." Exp. Clin. Endocrinol. 101:7-11 (1993).							
	CL	Sorscher et al. "Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines." Gene Therapy 1:233-238.					
Spector, David J. "The Pattern of Integration of Viral DNA Sequences in the Adenov 5-Transformed Human Cell Line 293." Virology 130:533-538 (1983). Stewart et al. "Difference imaging of adenovirus: bridging the resolution gap betwee ray crystallography and electron microscopy." EMBO Journal 12:2589-2599 (1993).				e Adenovirus			
				p between X- 9 (1993).			
	со	Supersaxo et al. Pharm. Res. 5(8):472	-476 (1988).				
	СР	Straus, S.E. "Adenovirus infections in New York: Plenum Press, 451-496 (19		Adenoviruses. H.S. G	insberg (ed.),		
	cq	Takahashi et al. "p53: A Frequenct Target for Genetic Abnormalities in Lung Cancer." Science 246:491-494 (1989).					
	CR	Takahashi et al. "Wild-type but not M Cancer Cells Bearing Multiple Geneti	utant p53 Suppr c Lesions." Can	resses the Growth of I cer Research 52:2340	Human Lung 1-2343 (1992).		
	cs	Thimmappaya et al. "Adenovirus VAI mRNAs at Late Times after Infection.			slation of Viral		
	СТ	Wang et al. "Quantitation of mRNA b Sci. USA 86:9717-9721 (1989).	y the polymeras	e chain reaction." Pro	oc. Natl. Acad.		
	CU	Watanable et al. "Cell-specific Enhand alphaFetoprotein Gene." The Journal	cer Activity in a al of Biological	Far Upstream Region Chemistry 262:4812-	n of the Human 4818 (1987).		

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)

SEP 2 2 2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known			
Application Number	10/602,258		
Filing Date	June 23, 2003	•	
First Named Inventor	Gregory, Richard		
Art Unit	Not Yet Assigned		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	016930-005000US		

		FOREIGN PA	TENT DOCUME	NTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁸ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
	cv	White et al. "The 19-Kilodalton Adenovirus E1B Transforming Protein Inhibits Programmed Cell Death and Prevents Cytolysis by Tumor Necrosis Factor .alpha" Mol. Cell. Biol. 12:2570-2580 (1992).				
	cw	Wills et al. Human Gene Therapy 5:1079-1088 (1994).				
	сх	Yonish-Rouach et al. "Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6." Nature 352:345-347 (1991).				
	CY Casez et al., Oncogene, vol. 6(10), pp. 1791-1797, 1991.					
	cz	Haj-Ahmad and Graham, Developmen and its use in the transfer of the herpes 57(1): 267-274, Jan. 1986.	t of a helper-ind simplex virus t	lependent human ader hymidine kinase gene	novirus vector , J. Virol.	
	Winnacker, E.L., From Genes to Clones, pp. 342-343, VCH Publishers, New York, NY, 1987.					

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.